Skip to content

Study of disease response in patients of Cancer of Cervix treated with a new technique of delivering radiation(Intensity Modulated Radiation Therapy)

Assessment of clinical outcomes in patients of Carcinoma Cervix treated with Intensity Modulated Radiation Therapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/11/010438
Enrollment
84
Registered
2017-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Carcinoma Cervix

Interventions

Intervention1: Intensity Modulated Radiotherapy: Intensity Modulated Radiotherapy by virtue of its ability to modify beamlet intensities has the potential to deliver higher dose to the target volumes

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All biopsy-proven patients of carcinoma cervix 2. FIGO Stages 1b2-IVa

Exclusion criteria

Exclusion criteria: 1. Patients with an ECOG Performance Status >2 2. Poor renal function tests (Serum Creatinine >1.2mg/dL) 3. Patient who had undergone previous pelvic surgery or irradiation 4. Patients with second malignancy 5. Patients

Design outcomes

Primary

MeasureTime frame
To calculate the proportion of patients achieving complete tumor response among patients with carcinoma cervix stages IB2-IVA receiving IMRT in our department.Timepoint: To calculate the proportion of patients achieving complete tumor response among patients with carcinoma cervix stages IB2-IVA receiving IMRT in our department 6 months from completion of treatment.

Secondary

MeasureTime frame
1. To determine the proportion of patients developing selected acute and late toxicities 2. To evaluate the association of disease, dose and host-related factors with tumor response and selected toxicities Timepoint: The toxicities will be documented upto 6 months after completion of treatment.

Countries

India

Contacts

Public ContactDr Kombathula Sri Harsha

Jawaharlal Institute of Post Graduate Medical Education and Research

drjagadesanp@gmail.com7418218771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026